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Abstract 
Asthenia-fatigue syndrome (AFS) is defined as a persistent, subjective sense of tiredness related to cancer or 
its treatment and greatly impacts quality of life among cancer patients. All tyrosine kinase inhibitors, but 
especially sunitinib, may induce AFS. The reason for sunitinib-induced AFS is not yet well understood. 
Adverse events caused by sunitinib associated with AFS may include anemia, hypothyroidism, nausea and 
vomiting. However, AFS is also reported when active treatment with sunitinib is ongoing, and no other 
relevant adverse event can justify it. The molecular mechanisms by which sunitinib triggers AFS remain 
elusive. Sunitinib displays multiple off-target tyrosine-kinase interactions and competitively inhibits multiple 
proteins through the blockade of their ATP-binding sites. The broad spectrum of kinases inhibited may play a 
key role not only in terms of activity but also in terms of toxicity induced by sunitinib. This study considered 
different clinical observations and current metabolic and pharmacological knowledge, leading to hypotheses 
regarding which molecular mechanisms may be involved in sunitinib-induced AFS in cancer patients. Deeper 
knowledge of the molecular mode of action of sunitinib may lead to improved optimization of its clinical use. 
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Introduction 
Asthenia-fatigue syndrome (AFS), one of the most common symptoms experienced by cancer 
patients, consists of poor endurance and impaired motor and cognitive function. The National 
Comprehensive Cancer Network (NCCN) defines fatigue as “a persistent, subjective sense of 
tiredness related to cancer or its treatment that interferes with usual functioning.”1 To describe 
fatigue, health professionals may use terms such as asthenia, lassitude, prostration, lack of energy 
and weakness. Cancer patients may describe AFS by saying that they feel tired, weak, exhausted, 
heavy or slow.  
 
Cancer patients treated with different tyrosine-kinase inhibitors, including sunitinib, experience 
AFS as a common side effect. Sunitinib-associated AFS is believed to be related to the presence of 
anemia, hypothyroidism and metabolic disturbances induced by tyrosine kinase inhibitors. 
However, fatigue is usually found in the absence of low hemoglobin or thyroid hormone levels. 
Little is known about the molecular mechanisms that drive this symptom. 
The Importance of Asthenia in Cancer Patients 
Asthenia is a multifactorial syndrome that dramatically affects the to quality of life in patients 
with advanced cancer. The impact of asthenia in those patients was clearly shown in a smart study 
conducted by The Fatigue Coalition in 1997, in which it was shown that asthenia affects a 
patient’s daily life more adversely than cancer-related pain (61 vs. 19%, respectively).2 
Furthermore, asthenia is present in nearly all patients with advanced-stage tumors.
3
 The asthenia 
found in cancer patients may be due to cytokines secreted by the tumor, adverse events derived 
from anticancer treatments, hyporexia/cachexia, mood abnormalities, such as depression or 
reduced levels of circulating hormones (e.g., hypogonadism and hypothyroidism).
4
 
 
Although numerous attempts to relieve the symptoms of asthenia with various drugs have 
occurred over the last two decades, only exercise has effectively improved asthenia in patients 
with cancer.
5
 Currently, no study has tested drug effectiveness related to cancer-related asthenia. 
Recently, methylphenidate was proven to be no more effective than placebo as palliative treatment 
for cancer-related fatigue.
6
 The management of asthenia remains an unmet need in clinical daily 
practice and is limited to correcting the hormonal or blood count parameters. 
 
The lack of effective pharmacological treatments for asthenia implies that this adverse event 
should be avoided whenever possible. 
Molecular Mechanism of Action for Sunitinib 
Sunitinib is a multitargeted tyrosine-kinase inhibitor designed to inhibit various receptor 
tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGFR) types-1, 
-2 and -3, platelet-derived growth factor receptors (PDGFRα and PDGFRβ), and the stem cell 
factor receptor KIT, FLT3 and RET, when administered at doses in the nanomolecular range.
7-9 
Sunitinib is characterized by a molecular similarity to ATP; therefore, sunitinib molecules 
compete with ATP for binding to the intracellular ATP-binding pocket of the tyrosine-kinase 
receptors that trigger the molecular routes that lead to functional effects such as cell growth, tumor 
proliferation, angiogenesis, etc.
10
 Most, if not all, protein kinases identified in the human genome 
have an ATP-binding site.
11
 Due to the similarity to ATP, sunitinib not only binds to these 
previously mentioned receptors but also binds to at least 68 other kinases. The clinical importance 
of inhibiting off-target kinases such as JAK1, the calcium/calmodulin protein kinases, or several 
cyclin-dependent kinases (CDKs) is not yet known, but it is believed that some toxicity may be 
induced by this inhibition.
12
 
  
A deeper knowledge of the activity and adverse events induced by off-target kinases will help 
us to more effectively select patients for sunitinib treatment in clinical practice.
13
 
The Incidence and Severity of Asthenia in Sunitinib Treated Patients and Related Clinical 
Management 
The incidence of asthenia or fatigue is a very common symptom to anti-angiogenic therapies 
for which no specific cause can usually be identified. In a retrospective analysis performed in two 
tertiary oncology centers in the USA for all patients with metastatic renal cell carcinoma treated 
out of a clinical trial showed that incidence of fatigue was 53%, 40% and 40% at any grade and 
11%, 10% and 4% considering only at grade 3/4 for sunitinib, sorafenib and bevacizumab 
respectively.
14
 Asthenia, together with hypertension and skin toxicity, were the dose limiting 
toxicities found in phase I trials with sunitinib administered as a single agent. In these early 
studies, grade 3 or 4 asthenia occurred mostly when the plasma levels of sunitinib increased to 
levels over 100 ng/ml.
15
 Renal cell carcinoma patients treated with sunitinib in either phase II or 
phase III trials experienced different toxicities and adverse events, including asthenia, 
dermatologic disturbances, intestinal toxicity and hypertension. Among these side effects, asthenia 
is the most common event associated with sunitinib administration (64–68% at any grade; 16% 
grade 3 or 4), although its intensity and effect on quality of life varied.
16
 Fatigue typically occurs 
2–3 weeks after the initiation of treatment and may intensify during weeks 3 or 4, sometimes 
representing a recurrent problem, although severity appears to vary throughout treatment. 
 
Several treatable and non-treatable factors may contribute to fatigue and weakness in patients 
with renal cell carcinoma (RCC). These factors include pain, emotional distress, anemia, sleep 
disturbance, nutrition, hypophosphatemia and hypomagnesemia, activity levels, hypothyroidism 
and comorbid conditions. Fatigue and asthenia may also be caused or exacerbated by underlying 
dehydration, and care should be taken to ensure patients have adequate fluid intake. Patients at 
high risk of fatigue or asthenia include elderly, frail or obese patients and those with a large tumor 
burden. 
 
Prior to treatment, patients should be counseled on what to expect from treatment, and 
psychological support should be provided when feasible. During the first 2 to 3 cycles of 
treatment, it is important to provide close support to counsel and motivate the patient on how to 
cope with fatigue and weakness. If quality of life is compromised because of fatigue or asthenia, 
the dose of sunitinib should be reduced. During every cycle, patients should be monitored for 
anemia, hypothyroidism and depression, and the appropriate treatment should be initiated. In 
patients with symptoms suggestive of hypothyroidism, the laboratory monitoring of thyroid 
function and subsequent treatment according to standard medical practice are recommended. 
Thyroid function should also be monitored in patients with severe asthenia and in those with a 
reduction of 20% in Karnofsky performance status.
17
 The half life for the appearance of asthenia is 
approximately 8 d, and the maximum level of asthenia is reached after one cycle of treatment with 
sunitinib.
18
 
 
The origin of sunitinib-associated asthenia is difficult to explain. One possible explanation is 
that sunitinib may cause thyroid dysfunction
19
 and, as a consequence, anemia, which could in turn 
contribute to fatigue in patients. 
Influence of Asthenia in Clinical Outcome 
Sunitinib is approved multinationally for the treatment of advanced renal cell carcinoma 
(RCC), metastatic gastrointestinal stromal tumors (GIST) after progression or intolerance to 
imatinib, and has recently received the approval by the European Medicine Agency (EMA) for the 
treatment of patients with advanced pancreatic islet cells neuroendocrine tumors (pNETs).
20-22
 
Houk and colleagues showed in a smart pharmacokinetic and pharmacodynamics meta-analysis 
the linear correspondence between dose level and efficacy and toxicity in more than 400 patients 
treated with sunitinib under clinical trials.
23
 In this sense, the results demonstrated that the highest 
oral exposure to sunitinib in time the greatest overall objective response rate, and longer 
progression free survival and overall survival with statistically significant difference. As expected, 
the increased exposure to sunitinib was also associated with the appearance and severity of adverse 
events. The proper management of adverse drug effects allows a better optimization of its 
efficiency and improves clinical outcomes. The incidence of fatigue was also correlated with 
sunitinib dose intake. However, no significant relationship was found between exposure to drug 
and neither severity of the fatigue nor the grade of fatigue have clearly been associated with 
clinical efficacy. 
Molecular Mechanism for Sunitinib-Induced Asthenia 
RTKs are transmembrane proteins located at the cell surface that possess extracellular ligand-
binding and intracellular catalytic domains to convey environmental signals to the cell nucleus.
24
 
RTKs require ATP to start the phosphorylative cascade and to convey signals. Sunitinib displays a 
structure analogous to that of ATP, whereby it is able to competitively inhibit multiple RTKs 
through the blockade of their ATP-binding sites. 
 
The exact mechanism involved in sunitinib-associated AFS remains elusive. However, 
sunitinib induces a decrease in blood glucose levels,
25
 which interferes with the IGF-1 pathway. 
According to other authors, this phenomenon could be partially related to a significant quantitative 
and qualitative capillary regression in pancreatic islets,
26
 interference with the insulin signaling 
pathway,
27
 and alteration in glucose transport. Because sunitinib shows low target specificity and 
binds to the ATP-binding sites of both multiple RTKs and other unidentified proteins, it could act 
as a toxic agent in multiple metabolic and physiological processes. One example of an unspecific 
sunitinib interaction is the binding to the ATP-binding cassette (ABC) transporters ABCB1 (P-
glycoprotein), ABCC1 (multidrug resistance-associated protein), and ABCG2.
28
 As ABC-
transporters are involved in the cellular influx and efflux of different metabolites and drugs 
(including sunitinib), the interaction between the ABC transporters and sunitinib could affect 
clinical outcomes by impairing drug delivery to cells and/or drug expulsion and detoxification. 
 
Other examples of potential off-target interactions of sunitinib with different kinases, 
pathways, proteins (e.g., AMP-activated protein kinases (AMPK), HIF1 (hypoxia inducible factor 
1), and facilitative sugar transporters (GLUTs)) are analyzed below. 
AMP-activated protein kinase (AMPK) and sunitinib. AMP-activated protein kinase (AMPK) 
is a key component in different signaling pathways, acting as an energy sensor responsible for the 
maintenance of energy balance within the cell (Fig. 1). AMPK is activated during events entailing 
metabolic stress, such as nutrient starvation or intense exercise. As a result, AMPK activates a set 
of energy producing pathways and inhibits energy consuming pathways.
29
 Thus, AMPK responds 
to an increase in the AMP:ATP ratio (caused by ATP depletion) and acts to balance the levels of 
ATP consumption and generation via anabolic and catabolic pathways.
30
 This role for AMPK is 
particularly relevant in tissues with a very high energy demand and robust ATP consumption. 
  
 
 
 
Figure 1. AMPK (AMP-activated protein kinase) is able to phosphorylate a set of targets for regulating numerous 
processes in response to energy depletion. These intermediary targets are in turn able to enhance (black arrows) or inhibit 
(red lines) different processes (such as glucose transport and metabolism, the management of fatty acids or protein 
synthesis). 
All cells need to maintain a high ATP:ADP ratio to survive. The ATP:ADP ratio usually 
remains approximately constant, which is indicative of the efficiency of the mechanisms that 
maintain this ratio (Fig. 2).
31
 In metabolic stress situations, when the cell is subjected to oxygen 
insufficiency and/or nutrient starvation, the ADP:ATP ratio increases due to energy deficiency. In 
these situations, the action of adenylate kinase (catalyzing the reaction 2ADP → ATP + AMP) 
maintains a minimum of ATP but also generates AMP. As a result, the AMP:ATP ratio increases, 
resulting in the cell’s metabolic status being compromised. The increase in the intracellular 
AMP:ATP ratio triggers the phosphorylation and activation of AMPK, which subsequently 
modulates the activity of multiple downstream targets to balance ATP levels.
31
 Thus, activated 
AMPK is able to phosphorylate and inhibit key regulatory components of signaling and anabolic 
pathways, including tuberous sclerosis 2 (TSC2), the mammalian target of rapamycin (mTOR), 
and acetyl-CoA carboxylase.
31,32
 However, AMPK is phosphorylated and activated by the 
upstream serine-threonine kinase LKB1.
33,34
 Recently, it was demonstrated that wild-type LKB1 is 
required to modulate the activity of AMPK and downstream targets in cells with depleted energy 
stores, including cancer cells.
35 
  
 
 
 
Figure 2. AMPK (AMP-activated protein kinase) is activated in response to an increase in AMP concentration and ATP 
depletion. The binding of AMP to the γ subunit of AMPK activates AMPK and prevents dephosphorylation of the activated 
phosphorylated form of the complex. Additionally, AMPK is activated by upstream protein kinases, including LKB1 and 
Ca2+/calmodulin dependent protein kinase β. Once activated, AMPK phosphorylates a set of downstream targets, enhancing 
catabolic processes to obtain ATP and inhibiting anabolic processes to prevent ATP consumption. 
Therefore, the inhibition, impairment or malfunction of AMPK leads to dramatic molecular 
alterations, which compromise the metabolic stability of the organism. Because AMPK is inhibited 
by sunitnib,
36-38
 patients subjected to treatment with this drug are unable to control and measure 
their energy availability, which may contribute to their lack of energy, weakness and asthenia. 
Oxygen, sugar and sunitinib. Oxygen is necessary for ATP generation because oxygen acts as 
the final electron acceptor in the mitochondrial electronic transport chain. Under hypoxia, cells are 
unable to reoxidize NADH and FADH generated during the oxidation of different carbon sources 
(including sugars from glycolysis) in the tricarboxylic acid cycle. Therefore, when cells are 
subjected to a hypoxic environment, they undergo a catabolic change. Energy/ATP generation 
becomes dependent almost exclusively on glycolysis. Therefore, cells activate fermentative 
reactions to reoxidize the NADPH generated during glycolysis and to allow this process to 
continue. In addition, cells under hypoxia have difficulties utilizing alternate carbon sources (such 
as amino acids and fatty acids) and are forced to use glucose as the primary source of energy. 
Because fermentative metabolism is considerably less efficient than oxidative phosphorylation in 
obtaining energy from glucose, hypoxic cells are forced to increase the rate of glucose uptake to 
fulfill energy demands. Due to their explosive and uncontrolled growth, cancer cells are frequently 
exposed to hypoxic conditions in tumors. Therefore, the increase in glucose uptake and the use of 
fermentative metabolism are hallmarks for cancer cells and tumors. The facilitative sugar 
transporters (GLUTs) are deregulated in various types of cancer.
39
 Because this phenomenon was 
first described by Otto Heinrich Warburg in 1956, it is known today as the “Warburg effect.”40,41 
 
HIF1, a heterodimeric transcription factor composed of α and β subunits, plays a key role in the 
metabolic adaptation of cancer cells to hypoxia.
42
 When oxygen availability is low, the α subunit is 
stabilized and translocated to the nucleus to dimerize with its β counterpart. Together, both 
subunits form the complete HIF1 transcription factor, which regulates a wide set of target genes 
(Table 1).
43
 Among HIF targets, there are genes necessary for survival under oxygen deprivation, 
including those involved in glucose uptake and glycolysis.
44,45
 
  
Table 1. HIF1 gene targets and processes where they are involved 
Process Genes 
  
Oxygen transport Erithropoietine (erithropoiesis) 
 Transferrine (Fe transport) 
 Transferrine receptor (Fe uptake) 
Vascular regulation Vascular endothelial growth factor, VEGF (angiogenesis) 
 Induced Nitric Oxide Synthase, iNOS (nitric oxide production) 
 Endothelin 1 (vascular tone regulation) 
Anaerobic metabolism Glucose transporter 1 (glucose uptake) 
 Phosphofructokinase (glycolysis) 
 Lactate dehydrogenase (glycolysis) 
Cell proliferation Insulin-like growth factor 2, IGF2 
 IGF transporter proteins 1 and 3 
  
 
Recently, it has been demonstrated that sunitinib is able to block the expression and activity of 
HIF1 in tumor cells under hypoxia,
46
 and, therefore, HIF1 transcriptional targets (such as the 
glucose transporter GLUT1) are no longer induced. Sunitinib could indirectly impair the 
mechanisms by which cancer cells obtain essential carbon sources and energy (sugar uptake and 
glycolysis). 
 
Our data indicate that sunitinib triggers an alteration in GLUT expression in both kidney tumor 
cell lines and renal cell carcinoma patients.
39
 Therefore, the sequestration of energy and carbon 
sources from tumor cells is an additional effect of sunitinib that contributes to its anticancer 
efficacy. Obviously, sunitinib, as a systemic drug, can also act on normal cells and potentially 
induce a general deregulation of glycolysis and sugar uptake, triggering the AFS observed in 
treated cancer patients. 
Exercise and sunitinib. In skeletal muscle, exercise triggers the stimulation of glucose transport, 
whether induced by insulin-independent mechanisms (based on the increase of contractile activity) 
or by insulin-dependent mechanisms. Thus, the cellular machinery of skeletal muscle is equipped 
to respond to contractile activity with a rapid increase in glucose uptake to match the high 
glycolytic flux. As a result, the concentration of sugar transporters in the plasma membrane is 
increased through the mobilization and translocation of units from the GLUT4 reservoir 
sequestered in intracellular pools.
47
 Although the mechanism of insulin-dependent glucose uptake 
stimulation has already been explained,
48,49
 the exact mechanism responsible for glucose uptake 
stimulation in response to contractile activity remains elusive. Previous reports point to 
intracellular calcium as the key mediator of exercise-dependent glucose uptake stimulation by the 
activation of different pathways, such as the protein kinase C (PKC) signaling pathway. 
 
However, NO production and nitric oxide synthase (NOS) activity are dramatically increased 
in skeletal muscle subjected to intense contractile activity.
50,51
 Interestingly, NO production has a 
deep impact on the increase of blood flow to muscle under intense activity due to its function as a 
vasodilator. In addition, there is evidence that NO also acts as a signaling molecule, mediating 
both immediate and long-term adaptive responses of muscle cells to the increase in activity.
52,53
 
Thus, NO stimulates muscular glucose uptake through a cGMP-mediated mechanism.
54
 
Conversely, the inhibition of NO production can block exercise-dependent stimulation of glucose 
uptake.
55
 However, studies in humans subjected to exercise have produced conflicting results on 
the effects of NOS inhibition and NO production blockade on glucose uptake.
56
 NOS activity and 
NO production are also linked with AMPK signaling and the increase in glucose uptake during 
exercise. Thus, during exercise, AMPK is activated in response to the increase in the AMP:ATP 
and creatine:phosphocreatine ratios,
57,58
 so that it is able to phosphorylate NOS and enhance NO 
production.
59,60
 
  
Therefore, since sunitinib is able to block AMPK activity,
36-38
 NOS activation and the increase 
in NO production in response to exercise are also impaired. Therefore, NO ceases to stimulate 
exercise-dependent muscular glucose uptake and no longer induces vasodilation of blood vessels 
supplying carbon sources and oxygen to muscles. 
 
Under normal conditions, muscle cells subjected to intense exercise experience difficulties in 
fulfilling their energy requirements when oxidative phosphorylation and oxygen supply are 
insufficient. To resolve this issue, muscle cells activate fermentative metabolism and therefore 
increase glucose uptake. At the molecular level, these events are triggered by the activation of 
AMPK and HIF1.
44,61,62
 However, the muscle cells of patients treated with sunitinib are unable to 
respond to explosive and intense activity because the response mechanisms dependent on AMPK 
and HIF1 activation are blocked. In addition, in muscle cells treated with sunitinib, AMPK is 
unable to stop the anabolic reactions, and HIF1 is unable to activate in response to hypoxia, 
contributing to the increase in energy depletion and the limitation of the oxygen supply. As a 
result, when patients subjected to sunitinib treatment are exposed to intense and sudden activity, 
they display premature symptoms of exhaustion and fatigue, which result in the sensation of 
asthenia. 
Discussion 
Asthenia is the most distressing side effect observed in patients treated with TKIs, particularly 
sunitinib, and can severely impact the patient’s quality of life. Although asthenia is part of the 
adverse events in common to others anti-angiogenic agents like diarrhea, skin rash, stomatitis, 
hand-foot skin reaction (HFSR), hypothyroidism and hematological abnormalities, there is no 
clear correlation with a primary VEGF signaling interference.
63
 
 
Unfortunately, asthenia is frequently undiagnosed or ignored in cancer patients. Oncologists 
accept cancer-related fatigue as expected and normal, and patients are often not treated for fatigue 
symptoms because oncologists think there is not much they can do to manage this syndrome. It is 
necessary to achieve a deeper understanding of the molecular basis and mechanisms of action of 
antitumor agents to clinically manage adverse events. Considering different clinical observations 
and current metabolic and pharmacological knowledge, we propose a set of hypotheses that may 
explain the molecular mechanisms whereby sunitinib could elicit asthenia in cancer patients. 
 
Adequate management of asthenia is crucial for achieving successful outcomes in patients 
treated with sunitinib; increased exposure to sunitinib improves clinical outcomes in terms of time 
to tumor progression, tumor response rate and overall survival.
64
 
 
There is a positive relationship between exposure and incidence, but not severity, of asthenia in 
patients treated with sunitinib. Because asthenia is one of the most common causes of sunitinib 
dose reduction, there is a need to understand why this adverse event occurs and how to prevent and 
alleviate the issue. 
 
Our hypothesis is based on the possible sunitinib-mediated inhibition of different metabolic 
and signaling pathways involved in energy balance and cell nutrition. Sunitinib inhibits the AMPK 
pathway, which plays a key role in maintaining the cellular energy balance. In non-malignant 
cells, AMPK acts during energy stress events to prevent the excessive expenditure of ATP. This 
effect is achieved through the specific blockade of a set of anabolic, energy-consuming pathways 
and the stimulation of catabolic, energy-generating pathways.
61,62,65,66
 Our hypothesis is that, in 
cancer cells, given their high growth rate and over-consumption of ATP, AMPK is deregulated. 
The sunitinib-dependent blockade of AMPK
36-38 
inhibits the effects of this deregulation, such as 
the increase in sugar uptake. On the other hand, sunitinib is able to block HIF1 activity and 
expression.
46
 Since HIF1 enhances sugar uptake and glycolytic pathway activity,
44,62
 HIF1 
blockade leads to an additional level of inhibition with respect to the availability of cellular 
energy. Moreover, it has been demonstrated that AMPK activity is critical for HIF1 activity in 
cancer cells, so that the sunitinib-mediated inhibition of AMPK may act synergistically with the 
sunitinib-mediated inhibition of HIF1. Finally, sunitinib could act directly by blocking cellular 
access to sugars (modifying the expression and/or activity of sugar transporters) or impairing 
metabolic processing (acting on glycolytic enzymes). 
 
The sunitinib effects previously described could contribute to the energy deprivation of cancer 
cells and, therefore, to the antitumor efficacy of the drug. However, we should note that these 
same effects could be devastating for normal cells and could elicit diverse sunitinib-associated side 
effects, including AFS. The hypothetical sunitinib-dependent blockade of previously described 
pathways and mechanisms could decrease the cellular availability of nutrients and energy, which 
would lead to treatment-associated AFS. Therefore, because more specific targeted therapies are 
not developed, cancer patients and physicians should suffer and learn to manage, respectively, the 
side effects associated with current antitumor treatments. 
 
The dose reduction may imply a decrease in drug efficacy, then it is essential in the clinical 
management of cancer patients to maintain the dose as higher and as longer as possible. Fatigue 
rarely leads to dose reductions or treatment interruptions if managed appropriately. It is critical to 
foresee those factors contributing to the onset and exacerbation of fatigue, including pain, anemia, 
depression and hypothyroidism. An understanding of the molecular mechanisms by which current 
antitumor drugs cause their associated side effects will contribute to the future development of 
better antitumor drugs. 
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